Free Trial
→ Elon's next millionaires start October 24? (From Behind the Markets) (Ad)tc pixel
NASDAQ:BIVI

BioVie Q4 2026 Earnings Report

BioVie logo
$1.35 -0.05 (-3.57%)
As of 02:21 PM Eastern
This is a fair market value price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

BioVie EPS Results

Actual EPS
N/A
Consensus EPS
-$0.52
Beat/Miss
N/A
One Year Ago EPS
N/A

BioVie Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

BioVie Announcement Details

Quarter
Q4 2026
Date
8/24/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Powered by Quartr

Earnings Documents

BioVie's Q4 2026 Annual reportAnnual report
(10-K)

BioVie Earnings Headlines

BioVie (NASDAQ:BIVI) Downgraded by Wall Street Zen to Sell
October 3, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31081392
BioVie Highlights Bezisterim Phase II Data, Eyes FDA Path for Phase III Trials
September 29, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31062179
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. One day it's a ceasefire, the next it's bombs again. The back and forth may be masking a bigger story most investors are missing. See the real reason this conflict may never fully end.tc pixel
October 8 at 1:00 AM  |  Banyan Hill Publishing (Ad)
New to The Street Show 773 Premieres Tonight on Bloomberg Television, Featuring Glint, Sagtec Global, BioVie and SafeSpace Global
September 26, 2026  |  usatoday.comhttps://www.usatoday.com/press-release/story/44764/new-to-the-street-show-773-premieres-tonight-on-bloomberg-television-featuring-glint-sagtec-global-biovie-and-safespace-global/
BioVie Inc. (BIVI) Discussion of Phase 2 data on bezisterim in Long COVID and Parkinson's with focus on inflammation targets Transcript
September 23, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4949122-biovie-inc-bivi-discussion-of-phase-2-data-on-bezisterim-in-long-covid-and-parkinsons-with
BioVie’s NE3107 Long COVID Trial Completion: What Investors Should Watch Next
September 22, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/biovies-ne3107-long-covid-trial-completion-what-investors-should-watch-next?utm_source=marketbeat.com&utm_medium=referral
See More BioVie Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like BioVie? Sign up for Earnings360's daily newsletter to receive timely earnings updates on BioVie and other key companies, straight to your email.

About BioVie

BioVie (NASDAQ:BIVI) (NASDAQ: BIVI) is a clinical-stage biopharmaceutical company focused on developing therapies for complex diseases with significant unmet medical needs. Its research programs have centered on neurodegenerative disorders, including Alzheimer’s disease and Parkinson’s disease, as well as liver diseases associated with cirrhosis.

The company’s development portfolio has included NE3107, an investigational oral therapy being studied for potential anti-inflammatory and insulin-sensitizing effects in neurodegenerative conditions. BioVie has also developed BIV201, a continuous-infusion formulation of terlipressin intended for the treatment of ascites associated with liver cirrhosis. These products remain investigational and are not approved for commercial use in the United States.

BioVie conducts its drug-development activities primarily through clinical research and regulatory programs in the United States, working with research institutions, clinical investigators and other development partners. The company is headquartered in Nevada and has historically focused its resources on advancing its candidate therapies through clinical testing and potential regulatory approval.

BioVie’s leadership has included Chief Executive Officer Cuong Do, who has experience in the biopharmaceutical and healthcare industries. As a development-stage biotechnology company, BioVie does not currently operate a broad commercial product business and remains dependent on the progress of its clinical programs.

View BioVie Profile
Earnings Tools